Amarin Corporation plc
AMRNHealthcare|Drug Manufacturers - General|IE
$11.61
+0.04 (+0.30%)
Tangible Book / Share
$20.79
Cash / Share
$15.53
Financials
Financial Snapshot
Market Cap
$240.1M
Enterprise Value
$91.2M
Revenue (TTM)
$176.0M
Net Income (TTM)
-$19.1M
Cash & Investments
$323.4M
Net Cash
$315.8M
Free Cash Flow (TTM)
$71.2M
Operating CF (TTM)
$71.2M
Debt/Equity
0.02
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $98.3M | $73.6M | $249.2M | $644.6M | $500.9M | $454.1M | $309.4M | $320.7M | $294.2M | $302.8M | $323.4M | |
| Operating Cash Flow | -$71.8M | -$32.8M | -$94.7M | -$9.4M | -$21.7M | -$66.5M | -$180.0M | $6.9M | -$31.0M | $6.7M | $71.2M | |
| Free Cash Flow | -$71.8M | -$32.8M | -$94.8M | -$11.8M | -$22.0M | -$66.5M | -$180.0M | $6.9M | -$31.0M | $6.7M | $71.2M | |
| Capital Expenditure | -$21.0K | -$12.0K | -$58.0K | -$2.5M | -$252.0K | $2.41 | -$1.89 | -$24.1K | $2.00 | $0.00 | $4.00 | |
| Financing Cash Flow | $63.1M | $8.2M | $271.3M | $409.6M | -$58.9M | -$5.1M | -$378.8K | $230.9K | -$1.4M | -$2.0M | -$2.7M |
R&D Spending
R&D (TTM)
$18.3M
R&D Intensity
10.4%
R&D Growth vs Prior
-7.6%
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130.1M | $181.1M | $229.2M | $429.8M | $614.1M | $583.2M | $369.2M | $306.9M | $228.6M | $213.6M | $176.0M | |
| R&D Expense | $50.0M | $47.2M | $55.9M | $34.4M | $39.0M | $29.3M | $30.4M | $22.2M | $20.9M | $19.8M | $18.3M | |
| R&D % of Revenue | 38.4% | 26.0% | 24.4% | 8.0% | 6.3% | 5.0% | 8.2% | 7.2% | 9.1% | 9.3% | 10.4% | |
| SG&A | $111.4M | $134.5M | $227.0M | $323.6M | $463.3M | $408.3M | $304.4M | $199.9M | $152.3M | $115.0M | $77.7M |
Income Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $130.1M | $181.1M | $229.2M | $429.8M | $614.1M | $583.2M | $369.2M | $306.9M | $228.6M | $213.6M | $176.0M | |
| Cost of Revenue | $34.4M | $45.0M | $54.5M | $96.0M | $131.4M | $121.3M | $126.7M | $141.4M | $147.2M | $92.8M | $104.7M | |
| Gross Profit | $95.7M | $136.2M | $174.7M | $333.7M | $482.6M | $461.9M | $242.5M | $165.5M | $81.4M | $120.9M | $71.4M | |
| R&D | $50.0M | $47.2M | $55.9M | $34.4M | $39.0M | $29.3M | $30.4M | $22.2M | $20.9M | $19.8M | $18.3M | |
| SG&A | $111.4M | $134.5M | $227.0M | $323.6M | $463.3M | $408.3M | $304.4M | $199.9M | $152.3M | $115.0M | $77.7M | |
| Operating Income | -$65.6M | -$45.6M | -$108.2M | -$24.3M | -$19.7M | $10.5M | -$105.9M | -$56.6M | -$91.8M | -$13.9M | -$24.6M | |
| Interest Expense | $18.7M | $9.8M | $8.9M | $6.6M | $2.6M | $129.0K | $15.0K | $8.0K | $7.0K | $7.0K | $0.00 | |
| Pretax Income | -$76.4M | -$55.4M | -$116.3M | -$22.5M | -$17.3M | $11.3M | -$103.8M | -$53.7M | -$77.2M | -$36.0M | -$17.1M | |
| Net Income | -$86.3M | -$67.9M | -$116.4M | -$22.6M | -$18.0M | $7.7M | -$105.8M | -$59.1M | -$82.2M | -$38.8M | -$19.1M | |
| EPS (Diluted) | -8.20 | -5.00 | -7.80 | -1.32 | -1.00 | 0.38 | -5.20 | -3.00 | -4.00 | -1.80 | -1.05 | |
| EBITDA | -$56.5M | -$44.3M | -$106.6M | -$15.0M | -$12.7M | $14.3M | -$100.7M | -$50.7M | -$74.3M | -$33.0M | -$17.9M | |
| Shares Out. (M) | 10.59 | 13.53 | 14.86 | 17.13 | 19.09 | 20.12 | 20.06 | 20.38 | 20.55 | 20.75 | 20.82 |
Balance Sheet
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $98.3M | $73.6M | $249.2M | $644.6M | $187.0M | $219.5M | $217.7M | $199.3M | $121.0M | $134.9M | $156.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $314.0M | $234.7M | $91.7M | $121.4M | $173.2M | $167.9M | $166.9M | |
| Total Current Assets | $146.3M | $153.3M | $378.0M | $855.0M | $879.2M | $878.7M | $689.1M | $725.0M | $595.4M | $649.9M | $612.9M | |
| Total Assets | $167.0M | $161.6M | $385.7M | $882.2M | $966.0M | $1.07B | $886.2M | $831.7M | $685.3M | $670.8M | $634.1M | |
| Total Current Liabilities | $76.2M | $108.5M | $157.3M | $242.2M | $307.4M | $370.7M | $259.5M | $259.3M | $179.9M | $194.5M | $175.1M | |
| Long-Term Debt | $85.2M | $99.8M | $46.1M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $6.1M | $0.00 | |
| Total Liabilities | $176.1M | $226.7M | $233.4M | $273.9M | $338.5M | $401.0M | $290.8M | $279.6M | $199.2M | $211.5M | $189.7M | |
| Stockholders' Equity | -$9.1M | -$65.1M | $152.3M | $608.3M | $627.5M | $667.1M | $595.3M | $552.1M | $486.2M | $459.3M | $444.4M | |
| Retained Earnings | -$1.20B | -$1.27B | -$1.39B | -$1.41B | -$1.43B | -$1.42B | -$1.53B | -$1.59B | -$1.67B | -$1.71B | -$1.73B |
Cash Flow Statement
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$71.8M | -$32.8M | -$94.7M | -$9.4M | -$21.7M | -$66.5M | -$180.0M | $6.9M | -$31.0M | $6.7M | $71.2M | |
| Capital Expenditure | -$21.0K | -$12.0K | -$58.0K | -$2.5M | -$252.0K | $2.41 | -$1.89 | -$24.1K | $2.00 | $0.00 | $4.00 | |
| Free Cash Flow | -$71.8M | -$32.8M | -$94.8M | -$11.8M | -$22.0M | -$66.5M | -$180.0M | $6.9M | -$31.0M | $6.7M | $71.2M | |
| Investing Cash Flow | -$21.0K | -$12.0K | -$58.0K | -$2.5M | -$377.0M | $104.1M | $175.2M | -$25.6M | -$46.0M | $8.8M | -$1.1M | |
| Financing Cash Flow | $63.1M | $8.2M | $271.3M | $409.6M | -$58.9M | -$5.1M | -$378.8K | $230.9K | -$1.4M | -$2.0M | -$2.7M | |
| Issuance of Stock | $64.6M | $0.00 | $264.8M | $440.1M | $0.00 | $4.6M | $664.6K | $2.2M | $131.1K | $140.3K | $83.1K | |
| Repurchase of Stock | $0.00 | -$2.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $59.0K | |
| Net Debt Issuance | $0.00 | $11.6M | -$14.7M | -$31.7M | -$50.3M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $13.6M | $14.0M | $18.8M | $30.9M | $45.8M | $0.00 | $0.00 | $0.00 | $17.7M | $13.9M | -$6.5M | |
| Net Change in Cash | -$8.7M | -$24.6M | $176.5M | $397.8M | -$457.6M | $32.5M | -$5.2M | -$18.4M | -$78.4M | $13.5M | $67.3M |
Dilution Tracker
Shares Outstanding
21M
5-Year Share Growth
+8.7%
Stock Issuance (TTM)
$83.1K
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 10.59 | 13.53 | 14.86 | 17.13 | 19.09 | 20.12 | 20.06 | 20.38 | 20.55 | 20.75 | 20.82 | |
| Change vs Prior % | — | 27.7% | 9.8% | 15.2% | 11.5% | 5.4% | -0.3% | 1.6% | 0.8% | 1.0% | 0.4% | |
| Stock Issuance | $64.6M | $0.00 | $264.8M | $440.1M | $0.00 | $4.6M | $664.6K | $2.2M | $131.1K | $140.3K | $83.1K | |
| Stock Repurchase | $0.00 | -$2.8M | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $59.0K | |
| Stock Based Comp. | $13.6M | $14.0M | $18.8M | $30.9M | $45.8M | $0.00 | $0.00 | $0.00 | $17.7M | $13.9M | -$6.5M |
Margins & Profitability
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.6% | 75.2% | 76.2% | 77.7% | 78.6% | 79.2% | 65.7% | 53.9% | 35.6% | 56.6% | 40.5% | |
| Operating Margin % | -50.4% | -25.2% | -47.2% | -5.6% | -3.2% | 1.8% | -28.7% | -18.4% | -40.2% | -6.5% | -14.0% | |
| Net Margin % | -66.4% | -37.5% | -50.8% | -5.3% | -2.9% | 1.3% | -28.7% | -19.3% | -35.9% | -18.2% | -10.9% | |
| EBITDA Margin % | -43.5% | -24.5% | -46.5% | -3.5% | -2.1% | 2.4% | -27.3% | -16.5% | -32.5% | -15.5% | -10.2% | |
| FCF Margin % | -55.2% | -18.1% | -41.3% | -2.8% | -3.6% | -11.4% | -48.7% | 2.2% | -13.6% | 3.2% | 40.4% | |
| ROE % | 953.3% | 104.2% | -76.4% | -3.7% | -2.9% | 1.2% | -17.8% | -10.7% | -16.9% | -8.4% | -4.3% | |
| ROA % | -51.7% | -42.0% | -30.2% | -2.6% | -1.9% | 0.7% | -11.9% | -7.1% | -12.0% | -5.8% | -3.0% | |
| ROIC % | -53.8% | -60.0% | -41.2% | -3.5% | -3.0% | 1.0% | -16.9% | -9.9% | -18.2% | -2.9% | -5.3% | |
| R&D / Revenue % | 38.4% | 26.0% | 24.4% | 8.0% | 6.3% | 5.0% | 8.2% | 7.2% | 9.1% | 9.3% | 10.4% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.1% | 39.2% | 26.6% | 87.5% | 42.9% | -5.0% | -36.7% | -16.9% | -25.5% | -6.5% | |
| Gross Profit | 77.7% | 42.2% | 28.3% | 91.1% | 44.6% | -4.3% | -47.5% | -31.7% | -50.8% | 48.5% | |
| Operating Income | 33.2% | 30.6% | -137.6% | 77.6% | 19.0% | 153.4% | -1108.1% | 46.5% | -62.1% | 84.8% | |
| Net Income | 25.0% | 21.4% | -71.6% | 80.6% | 20.5% | 142.9% | -1468.9% | 44.1% | -39.0% | 52.8% | |
| EPS (Diluted) | 50.6% | 39.0% | -56.0% | 83.1% | 24.4% | 138.4% | -1454.2% | 42.3% | -33.3% | 55.0% | |
| Operating Cash Flow | 15.3% | 54.3% | -188.4% | 90.1% | -132.2% | -205.9% | -170.5% | 103.8% | -549.3% | 121.7% | |
| Free Cash Flow | 15.3% | 54.3% | -188.5% | 87.5% | -85.7% | -202.4% | -170.5% | 103.8% | -550.7% | 121.7% | |
| R&D Expense | -2.1% | -5.6% | 18.5% | -38.5% | 13.3% | -24.8% | 3.8% | -26.9% | -6.1% | -5.1% | |
| SG&A Expense | 10.2% | 20.8% | 68.7% | 42.6% | 43.2% | -11.9% | -25.4% | -34.3% | -23.8% | -24.5% | |
| Total Assets | -3.7% | -3.2% | 138.7% | 128.7% | 9.5% | 10.6% | -17.0% | -6.1% | -17.6% | -2.1% | |
| Book Value / Share | 94.0% | -459.3% | 313.1% | 246.5% | -1.8% | -3.4% | -11.9% | -5.6% | -15.6% | -6.5% | |
| Debt | -52.4% | 5.3% | -34.5% | -25.9% | -84.6% | -6.3% | 16.8% | -12.8% | -11.6% | 57.5% | |
| Diluted Shares | 17.3% | 27.7% | 9.8% | 15.2% | 11.5% | 5.4% | -0.3% | 1.6% | 0.8% | 1.0% |
Valuation
P/E (TTM)At Loss
P/S1.36
10Y Low / Med / High0.87 / 2.87 / 17.65
P/B0.54
10Y Low / Med / High0.41 / 2.00 / 26.56
EV/EBITDAAt Loss
EV/Revenue0.52
10Y Low / Med / High0.38 / 2.58 / 16.91
P/FCF3.37
Intrinsic Value Models (per share)
Tangible Book / Share
$20.79
Net Current Assets / Share
$20.46
Graham Net-Net
$14.25
Cash / Share
$15.53
| Metric | Trend | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -7.51 | -16.04 | -34.90 | -324.36 | -103.60 | 172.82 | -4.65 | -5.80 | -2.42 | -7.76 | -11.09 | |
| P/S Ratio | 4.99 | 5.99 | 17.65 | 17.09 | 2.87 | 2.29 | 1.31 | 1.12 | 0.87 | 1.36 | 1.36 | |
| P/B Ratio | -71.61 | -16.67 | 26.56 | 12.07 | 2.81 | 2.00 | 0.82 | 0.62 | 0.41 | 0.63 | 0.54 | |
| EV/EBITDA | -11.80 | -25.58 | -36.36 | -450.72 | -124.36 | 78.71 | -2.76 | -3.00 | -1.16 | -5.06 | -5.10 | |
| EV/Revenue | 5.13 | 6.26 | 16.91 | 15.73 | 2.58 | 1.93 | 0.75 | 0.50 | 0.38 | 0.78 | 0.52 |
Analyst Estimates & Quality
Altman Z-Score
-2.05
Distress
Piotroski F-Score
4
Moderate
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $183.4M | $189.0M | $185.1M |
| Net Income | -$23.4M | -$13.0M | -$17.2M |
| EPS | $-1.13 | $-0.63 | $-0.83 |
| # Analysts (EPS) | 1 | 1 | 1 |
Revenue Segments
By Product
| Segment | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Licensing And Royalty | $7.0M | $2.9M | $2.7M | $21.6M | $24.0M | $30.9M |
| Product | $607.0M | $580.3M | $366.5M | $285.3M | $204.6M | $182.8M |
By Geography
| Segment | 2024 | 2025 |
|---|---|---|
| Europe | $13.7M | $18.4M |
| UNITED STATES | $166.7M | $154.1M |